Guggenheim analyst Vamil Divan upgraded Jade Biosciences (JBIO) to Buy from Neutral with a $14 price target
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on JBIO:
- Jade Biosciences presents JADE101 preclinical data at ERA Congress
- Is AVTE a Buy, Before Earnings?
- Promising Future for Jade Biosciences: Buy Rating Backed by Innovative JADE101 and Experienced Leadership
- Jade Biosciences Updates Corporate Presentation
- Jade Biosciences initiated with an Outperform at Wedbush